Literature DB >> 3039052

Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS.

C Farthing, M G Anderson, M E Ellis, B G Gazzard, A C Chanas.   

Abstract

Foscarnet was administered to eight AIDS patients for suspected cytomegalovirus (CMV) pneumonitis as a continuous intravenous infusion for a minimum of 8 days. All the patients improved, three showing complete resolution of symptoms. Evidence of CMV infection from bronchoalveolar lavage samples was lacking in two patients. Adverse drug experiences consisted of thrombophlebitis, transient decreases in haemoglobin concentration, and reversible rises in serum creatinine levels.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3039052     DOI: 10.1002/jmv.1890220206

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  13 in total

1.  Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.

Authors:  R Snoeck; G Andrei; D Schols; J Balzarini; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

Review 2.  Acquisition of cytomegalovirus infection: an update.

Authors:  B A Forbes
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

3.  Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro.

Authors:  J F Manischewitz; G V Quinnan; H C Lane; A E Wittek
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

Review 4.  Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.

Authors:  P Chrisp; S P Clissold
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

5.  Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.

Authors:  F Aweeka; J Gambertoglio; J Mills; M A Jacobson
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

6.  Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro.

Authors:  B F Eriksson; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

7.  Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.

Authors:  R F Omar; N Dusserre; A Désormeaux; L Poulin; M Tremblay; D Beauchamp; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 8.  Adverse effects of drugs used in the management of opportunistic infections associated with HIV infection.

Authors:  B S Peters; E Carlin; R J Weston; S J Loveless; J Sweeney; J Weber; J Main
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

9.  Age-related differences in phosphonoformate-induced bone toxicity in cats.

Authors:  C L Swenson; S E Weisbrode; L A Nagode; K A Hayes; C L Steinmeyer; L E Mathes
Journal:  Calcif Tissue Int       Date:  1991-05       Impact factor: 4.333

10.  Toxicity of intravitreal injection of foscarnet in the rabbit eye.

Authors:  S C She; G A Peyman; J A Schulman
Journal:  Int Ophthalmol       Date:  1988       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.